KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Buildings (2009 - 2013)

Pfizer (PFE) reported Buildings of $10.1 billion for Q4 2013, down 5.52% year-over-year from $10.6 billion in Q4 2012, and down 5.52% on a QoQ basis from $10.6 billion in Q4 2012.

Pfizer (PFE) has 5 years of Buildings data on file, last reported at $10.1 billion in Q4 2013.

  • Quarterly Buildings fell 5.52% year-over-year to $10.1 billion in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $10.1 billion (down 5.52% YoY) and the FY2013 annual result came in at $10.1 billion, down 5.52% from the prior year.
  • Buildings retreated to $10.1 billion in Q4 2013 per PFE's latest filing, from $10.6 billion in the prior quarter.
  • Across five years, Buildings topped out at $14.2 billion in Q4 2009 and bottomed at $10.1 billion in Q4 2013.
  • The 5-year median for Buildings is $12.1 billion (2011), against an average of $12.0 billion.
  • The widest annual swing landed in 2012, when Buildings dropped 11.96%; it then declined 5.52% in 2013.
  • Tracing PFE's Buildings over 5 years: stood at $14.2 billion in 2009, then dropped by 6.95% to $13.2 billion in 2010, then retreated by 8.42% to $12.1 billion in 2011, then retreated by 11.96% to $10.6 billion in 2012, then slipped by 5.52% to $10.1 billion in 2013.
  • Per Business Quant, the three latest PFE Buildings figures stand at $10.1 billion (Q4 2013), $10.6 billion (Q4 2012), and $12.1 billion (Q4 2011).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2013 10.06 Bn
Dec 31, 2012 10.64 Bn
Dec 31, 2011 12.09 Bn
Dec 31, 2010 13.20 Bn
Dec 31, 2009 14.19 Bn